Emergent BioSolutions Inc. EBS
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $742.9M | -29% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Gross profit | $317.6M | -17% | FY ending Dec 31, 2023 |
| Operating income | $100.1M | +192% | FY ending Dec 31, 2025 |
| Net income | $52.6M | +128% | FY ending Dec 31, 2025 |
| Earnings per share | $0.93 | +126% | FY ending Dec 31, 2025 |
| Research & development | $53.2M | -25% | FY ending Dec 31, 2025 |
| Cash from operations | $170.6M | +191% | FY ending Dec 31, 2025 |
| Capital spending | $13.8M | -40% | FY ending Dec 31, 2025 |
| Share buybacks | $24.9M | FY ending Dec 31, 2025 | |
| Cash | $205.4M | +106% | FY ending Dec 31, 2025 |
| Long-term debt | $572.1M | -14% | FY ending Dec 31, 2025 |
| Shareholders' equity | $522.6M | +8% | FY ending Dec 31, 2025 |
| Shares outstanding | 52M | -4% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 11 sales ($1.3M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Donald W DegolyerDirector | Soldpre-set plan | 17,800 | $7.09 | $126K | Oct 7, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Soldpre-set plan | 3,000 | $6.53 | $20K | Oct 1, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Soldpre-set plan | 3,000 | $8.40 | $25K | Jul 1, 2026 |
| Kathryn C ZoonDirector | Soldpre-set plan2 fills | 17,202 | $8.40 avg | $144K | May 1, 2026 |
| Donald W DegolyerDirector | Soldpre-set plan2 fills | 15,481 | $8.40 avg | $130K | May 1, 2026 |
| Sujata Tyagi DayalDirector | Soldpre-set plan2 fills | 13,761 | $8.40 avg | $116K | May 1, 2026 |
| Keith KatkinDirector | Soldpre-set plan | 15,481 | $8.28 | $128K | Apr 30, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Soldpre-set plan | 4,000 | $8.44 | $34K | Apr 1, 2026 |
| Ronald RichardDirector | Sold2 fills | 21,984 | $11.97 avg | $263K | Dec 5, 2025 |
| Donald W DegolyerDirector | Soldpre-set plan | 17,801 | $10.54 | $188K | Nov 10, 2025 |
| Sujata Tyagi DayalDirector | Soldpre-set plan | 8,552 | $10.00 | $86K | Nov 7, 2025 |
Other insider moves (44): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Richard S LindahlEVP, Chief Financial Officer | Tax withholding | 3,964 | $8.00 | $32K | Jun 8, 2026 |
| Coleen GlessnerEVP, Quality & Ethics, and CPL | Tax withholding | 2,018 | $8.00 | $16K | Jun 8, 2026 |
| William HartzelSVP, Bioservices | Tax withholding | 1,741 | $8.00 | $14K | Jun 8, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Tax withholding | 694 | $8.00 | $5,552 | Jun 8, 2026 |
| Sujata Tyagi DayalDirector | Awardpre-set plan | 25,344 | – | – | Apr 30, 2026 |
| Donald W DegolyerDirector | Awardpre-set plan | 25,344 | – | – | Apr 30, 2026 |
| Keith KatkinDirector | Awardpre-set plan | 25,344 | – | – | Apr 30, 2026 |
| Marvin L WhiteDirector | Award | 25,344 | – | – | Apr 30, 2026 |
| John D Jr FowlerDirector | Award | 25,344 | – | – | Apr 30, 2026 |
| Ronald RichardDirector | Award | 25,344 | – | – | Apr 30, 2026 |
| Kathryn C ZoonDirector | Awardpre-set plan | 25,344 | – | – | Apr 30, 2026 |
| Neal Franklin FowlerDirector | Award | 25,344 | – | – | Apr 30, 2026 |
| Zsolt HarsanyiChairman, Director | Award | 25,344 | – | – | Apr 30, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Award | 100,111 | – | – | Apr 29, 2026 |
| Simon C LowrySVP, R&D, CMO | Award | 100,111 | – | – | Apr 29, 2026 |
| Coleen GlessnerEVP, Quality & Ethics, and CPL | Award | 100,111 | – | – | Apr 29, 2026 |
| Richard S LindahlEVP, Chief Financial Officer | Award | 162,680 | – | – | Apr 29, 2026 |
| Jessica PerlSVP, General Counsel, Corp Sec | Award | 104,282 | – | – | Apr 29, 2026 |
| William HartzelSVP, Bioservices | Award | 100,111 | – | – | Apr 29, 2026 |
| Joseph C PapaPresident and CEO, Director | Award | 187,708 | – | – | Apr 29, 2026 |
| Joseph C PapaPresident and CEO, Director | Tax withholding | 37,055 | $8.44 | $313K | Mar 5, 2026 |
| Richard S LindahlEVP, Chief Financial Officer | Tax withholding | 23,650 | $8.44 | $200K | Mar 5, 2026 |
| Simon C LowrySVP, R&D, CMO | Tax withholding | 10,636 | $8.44 | $90K | Mar 5, 2026 |
| William HartzelSVP, Bioservices | Tax withholding | 9,493 | $8.44 | $80K | Mar 5, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Tax withholding | 9,397 | $8.44 | $79K | Mar 5, 2026 |
| Coleen GlessnerEVP, Quality & Ethics, and CPL | Tax withholding | 8,199 | $8.44 | $69K | Mar 5, 2026 |
| Jessica PerlSVP, General Counsel, Corp Sec | Tax withholding | 6,465 | $8.44 | $55K | Mar 5, 2026 |
| John D Jr FowlerDirector | Award | 5,006 | $8.99 | $45K | Mar 3, 2026 |
| Richard S LindahlEVP, Chief Financial Officer | Tax withholding | 683 | $8.15 | $5,566 | Mar 1, 2026 |
| Coleen GlessnerEVP, Quality & Ethics, and CPL | Tax withholding | 313 | $8.15 | $2,551 | Mar 1, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Tax withholding | 116 | $8.15 | $945 | Mar 1, 2026 |
| Jessica PerlSVP, General Counsel, Corp Sec | Tax withholding | 918 | $11.03 | $10K | Feb 9, 2026 |
| Richard S LindahlEVP, Chief Financial Officer | Returned | 46,155 | $10.92 | $504K | Feb 6, 2026 |
| Coleen GlessnerEVP, Quality & Ethics, and CPL | Returned | 28,847 | $10.92 | $315K | Feb 6, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Returned | 8,655 | $10.92 | $95K | Feb 6, 2026 |
| William HartzelSVP, Bioservices | Returned | 5,771 | $10.92 | $63K | Feb 6, 2026 |
| Richard S LindahlEVP, Chief Financial Officer | Tax withholding | 5,642 | $10.92 | $62K | Feb 6, 2026 |
| Coleen GlessnerEVP, Quality & Ethics, and CPL | Tax withholding | 2,852 | $10.92 | $31K | Feb 6, 2026 |
| Paul Anthony WilliamsSVP, Products Business | Tax withholding | 1,022 | $10.92 | $11K | Feb 6, 2026 |
| William HartzelSVP, Bioservices | Tax withholding | 630 | $10.92 | $6,880 | Feb 6, 2026 |
| Simon C LowrySVP, R&D, CMO | Tax withholding | 3,543 | $11.41 | $40K | Dec 14, 2025 |
| Ronald RichardDirector | Tax withholding | 10,864 | $11.90 | $129K | Dec 5, 2025 |
| Ronald RichardDirector | Option exercise | 25,748 | $5.02 | $129K | Dec 5, 2025 |
| William HartzelSVP, Bioservices | Tax withholding | 610 | $10.88 | $6,637 | Nov 11, 2025 |
Trades by members of Congress
1 member reported 0 buys and 1 sale since Dec 11, 2024. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Steve Cohen D | Sold | $1,001–$15K | Dec 11, 2024 | Jan 10, 2025 | Self |
Latest SEC filings
- News filing: Executive or board change 8-K · Oct 16, 2026
- Insider plans to sell 144 · Oct 7, 2026
- Insider plans to sell 144 · Oct 1, 2026
- News filing: Public announcement (Reg FD) 8-K · Sep 14, 2026
- News filing: Other news 8-K · Sep 1, 2026
- Quarterly report 10-Q · Aug 6, 2026
- News filing: Quarterly results, Cost cuts or layoffs, Executive or board change, Public announcement (Reg FD) 8-K · Aug 5, 2026
- Insider plans to sell 144 · Jul 1, 2026
- News filing: Signed a major agreement, Public announcement (Reg FD) 8-K · Jun 29, 2026
- Insider plans to sell 144 · May 1, 2026
- Insider plans to sell 144 · May 1, 2026
- Insider plans to sell 144 · May 1, 2026
- Quarterly report 10-Q · May 1, 2026
- News filing: Quarterly results, Public announcement (Reg FD) 8-K · Apr 30, 2026
- Insider plans to sell 144 · Apr 30, 2026
- News filing: Shareholder vote results 8-K · Apr 30, 2026
- News filing: Signed a major agreement, Ended a major agreement, Sold unregistered shares, Public announcement (Reg FD) 8-K · Apr 17, 2026
- Insider plans to sell 144 · Apr 1, 2026
- Shareholder meeting proxy DEF 14A · Mar 20, 2026
- News filing: Executive or board change, Public announcement (Reg FD) 8-K · Mar 3, 2026
- Annual report 10-K · Feb 27, 2026
- News filing: Quarterly results, Public announcement (Reg FD) 8-K · Feb 26, 2026
- News filing: Public announcement (Reg FD) 8-K · Jan 14, 2026
- News filing: Public announcement (Reg FD) 8-K · Jan 12, 2026
- Insider plans to sell 144 · Jan 7, 2026
About Emergent BioSolutions Inc.
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- Gaithersburg, MD
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- NYSE
- Filer size
- Accelerated filer
- SEC company number (CIK)
- 1367644
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.